TP53 and neoplasm: Moreover, our study and others have demonstrated that successfully and unsuccessfully engrafted tumors exhibit a similar distribution of KRAS mutations and comparable expression or mutation of TP53. Collectively, these results suggest that that single genetic alterations may not be determinant of tumor engraftment, allowing PDX models of PDAC to recapitulate the broad genetic diversity of patient tumors.